Immunocore to present Phase 1 data on brenetafusp-Kimmtrak combination in metastatic uveal melanoma at SITC
IMCR•Immunocore will present Phase 1 data on brenetafusp combined with Kimmtrak in metastatic uveal melanoma at SITC on November 6-7, 2026.
1. SITC presentations
Immunocore will present Phase 1/2 trial findings on brenetafusp alone or in combination with Kimmtrak. Additional safety and efficacy findings are scheduled for a poster presentation on November 6, followed by a late-breaking oral presentation on November 7.
